News and reflections from the world of AI

    June 9, 2022

    Aiforia makes key advancement towards end-to-end clinical pathology workflow solution with the release of its CE-IVD marked Aiforia® Clinical Suite Viewer

    Aiforia Technologies Plc is thrilled to announce it received CE-IVD marking for the Aiforia® Clinical Suite Viewer, a cloud-based platform enabling a holistic approach to cancer diagnostics and prognostics through the viewing of whole slide digital images of human histopathological samples and deep learning AI produced results along with their seamless reporting. The Aiforia viewer provides ...
    Written by Aiforia
    May 27, 2022

    Aiforia releases another CE-IVD marked clinical AI Model — expanding its diagnostic pathology offering to prostate cancer

    This latest regulatory certification brings Aiforia’s portfolio of AI-powered diagnostic tools to a total of 5 CE-IVD marked clinical AI models for breast, lung, and now prostate cancer — the most commonly occurring cancer in men. According to the World Cancer Research Fund, more than 1.4 million new cases of prostate cancer were diagnosed in 2020. Both pathologists and patients deserve reliable ...
    Written by Aiforia
    May 25, 2022

    Aiforia adds fourth CE-IVD marked clinical AI Model to its rapidly expanding portfolio of novel tools for cancer diagnostics

    Aiforia is providing a uniquely comprehensive approach to breast cancer diagnostics as the majority of cases express ER and/or PR. Therefore, the two are considered to be the most significant biomarkers involved in the evaluation of breast cancer.
    Written by Aiforia
    May 5, 2022

    Aiforia Technologies Plc appoints Vice President of Sales for Europe

    Aiforia has appointed Tamas Regenyi as Vice President of Sales, Europe. The position will be essential to driving Aiforia’s business strategy in the region; focusing on accelerating growth in Aiforia’s established preclinical market in acquiring large customers in the pharmaceutical industry as well as advancing Aiforia’s position in the clinical diagnostics market for pathology.
    Written by Aiforia
    April 28, 2022

    Aiforia aims to set a new industry standard for customer support with the launch of its one of a kind Aiforia Community Platform

    Earlier this week Aiforia Technologies launched the Aiforia Community Platform — one of the only available platforms of this nature, for pathologists and scientists utilizing AI for image analysis software in preclinical and clinical settings. The company’s users, ranging from some of the world’s largest pharmaceutical companies to the world’s top ranked hospitals and medical institutions, now ...
    Written by Aiforia
    April 20, 2022

    Aiforia expands its portfolio of CE-IVD marked clinical pathology solutions with new AI model for breast cancer diagnostics

    Aiforia Technologies Plc, Press Release, 20 April, 2022 at 09.30 a.m. EEST. Aiforia Technologies Plc announces the CE-IVD marking of the Aiforia® Clinical AI Model for Breast Cancer; ER. Adding to its repertoire of CE-IVD marked clinical AI models for cancer diagnostics, the new AI model automates the calculation of estrogen receptors (ER) — a group of proteins present in the majority of breast ...
    Written by Aiforia
    2 3 4 5 6